OTCMKTS:STDAFSTADA Arzneimittel Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding STADA Arzneimittel AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $78.85 0.00 (0.00 %) (As of 06/4/2020 12:26 PM ET) Add Compare Share Today's Range$78.85Now: $78.85▼$78.8550-Day Range$75.04MA: $77.29▼$78.8552-Week Range$75.15Now: $78.85▼$105.00VolumeN/AAverage Volume0 shsMarket Capitalization$4.92 billionP/E RatioN/ADividend YieldN/ABeta0.5 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux. The Branded Products segment offers APO-Go for Parkinson's disease; Grippostad for cold; Aqualor for rhinitis/soare throat; Snup for rhinitis; and Vitaprost for prostate disease. It serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for STADA Arzneimittel. Previous Next 2.0 Community Rank Outperform VotesSTADA Arzneimittel has received 296 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSTADA Arzneimittel has received 426 “underperform” votes. (Add your “underperform” vote.)Community SentimentSTADA Arzneimittel has received 59.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimittel and other stocks. Vote “Outperform” if you believe STDAF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSTADA Arzneimittel does not currently pay a dividend.Dividend GrowthSTADA Arzneimittel does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, STADA Arzneimittel insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioSTADA Arzneimittel has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.40 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:STDAF Previous SymbolNASDAQ:STDAF CUSIPN/A CIKN/A Webwww.stada.com Phone49-6101-6030Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.75 billion Price / Sales1.79 Cash Flow$8.20 per share Price / Cash Flow9.62 Book Value$22.32 per share Price / Book3.53Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10,416 Outstanding Shares62,340,000Market Cap$4.92 billion Next Earnings DateN/A OptionableNot Optionable OTC:STDAF Rates by TradingView Receive STDAF News and Ratings via Email Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter. STADA Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions How has STADA Arzneimittel's stock been impacted by COVID-19 (Coronavirus)? STADA Arzneimittel's stock was trading at $88.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STDAF shares have decreased by 11.3% and is now trading at $78.85. View which stocks have been most impacted by Coronavirus. Has STADA Arzneimittel been receiving favorable news coverage? News headlines about STDAF stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. STADA Arzneimittel earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutSTADA Arzneimittel. Who are some of STADA Arzneimittel's key competitors? Some companies that are related to STADA Arzneimittel include Canopy Growth (CGC), Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Tilray (TLRY), Aphria (APHA), Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and True Drinks (TRUU). View all competitors. Who are STADA Arzneimittel's key executives? STADA Arzneimittel's management team includes the following people: Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 62)Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 55)Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 54)Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 44)Ms. Kay Reubelt, Director of Investor Relations What is STADA Arzneimittel's stock symbol? STADA Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF." How do I buy shares of STADA Arzneimittel? Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is STADA Arzneimittel's stock price today? One share of STDAF stock can currently be purchased for approximately $78.85. How big of a company is STADA Arzneimittel? STADA Arzneimittel has a market capitalization of $4.92 billion and generates $2.75 billion in revenue each year. STADA Arzneimittel employs 10,416 workers across the globe. What is STADA Arzneimittel's official website? The official website for STADA Arzneimittel is www.stada.com. How can I contact STADA Arzneimittel? STADA Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
